Vertex Pharmaceuticals | VRTX

Vertex Pharmaceuticals traded at $312.54 this Tuesday March 28th, increasing $4.07 or 1.32 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 7.32 percent. Over the last 12 months, its price rose by 21.15 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 304.39 by the end of this quarter and at 276.27 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
312.54
Daily Change
1.32%
Yearly
21.15%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 158.52 0.98 0.62% -2.26%
Acadia Pharmaceuticals 18.35 -0.25 -1.34% -27.53%
Acorda Therapeutics 0.58 0.01 1.40% -65.27%
Agios Pharmaceuticals 22.60 0.35 1.57% -25.85%
Alnylam Pharmaceuticals 188.57 -1.94 -1.02% 13.09%
Amgen 238.23 1.47 0.62% -1.37%
Arrowhead Research 24.32 -0.11 -0.45% -47.95%
Biogen 269.38 -0.60 -0.22% 25.32%
Bluebird Bio 4.33 -0.19 -4.10% -16.83%
BioMarin Pharmaceutical 91.10 -0.40 -0.44% 14.50%
Bristol-Myers Squibb 68.15 0.08 0.12% -6.94%
Gilead Sciences 80.86 1.28 1.61% 33.59%
Intercept Pharmaceuticals 13.79 -0.04 -0.29% -18.74%
Incyte Corp 70.24 -0.57 -0.80% -11.88%
Insmed 16.81 -0.43 -2.49% -27.51%
Ionis Pharmaceuticals 33.92 0.20 0.59% -7.02%
J&J 152.10 -1.20 -0.78% -14.43%
Merck & Co 105.70 -1.23 -1.15% 29.58%
Moderna Inc 146.79 -1.56 -1.05% -18.74%
Neurocrine Biosciences 96.49 -0.57 -0.58% 3.90%
Novartis 83.47 1.22 1.48% 2.34%
Puma Biotechnology 2.47 0.09 3.97% -15.25%
Pfizer 39.92 -0.30 -0.75% -24.31%
PTC Therapeutics 44.75 -1.02 -2.22% 15.06%
Ultragenyx Pharmaceutical 37.52 0.19 0.51% -47.52%
Regeneron Pharmaceuticals 820.88 0.47 0.06% 17.53%
Roche Holding 256.95 0.05 0.02% -31.07%
Sanofi 100.00 1.56 1.58% 8.70%
Seattle Genetics 202.78 3.18 1.59% 41.63%
Sangamo BioSciences 1.69 -0.06 -3.16% -73.17%
Sarepta Therapeutics 133.35 2.21 1.69% 69.40%
United Therapeutics 219.93 1.92 0.88% 23.24%
Vertex Pharmaceuticals 312.54 4.07 1.32% 21.15%

Indexes Price Day Year
US500 3966 -11.59 -0.29% -14.38%
USND 11685 -83.69 -0.71% -20.07%
US400 2431 4.50 0.19% -12.34%
USNDX 12581 -91.65 -0.72% -17.44%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.